SEC Form 4 · accession 0001445064-16-000209
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Meredith B Fischer
Officer — Sr. VP, Comm & Public Affairs
Period of report
Feb 26, 2016
Accepted (ET)
Mar 1, 2016 · 8:48 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 26, 2016 | P | 900 | $69.52 | A | 17,643 | D | |
| Ordinary SharesF2 | Feb 26, 2016 | P | 500 | $70.30 | A | 18,143 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $69.15 to $70.08, inclusive. Ms. Fischer will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
- F2The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $70.25 to $70.41, inclusive. Ms. Fischer will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.